IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re: Apple Tree Life Sciences, Inc., *et al.*,[1] Debtors.	Chapter 11 Case No. 25-12177 (LSS) (Jointly Administered)

RIGMORA BIOTECH INVESTOR ONE LP AND RIGMORA BIOTECH INVESTOR TWO LP EXHIBIT LIST FOR THE HEARING ON JANUARY 20, 2026 AT 2:30 P.M. (ET)

Parties in interest Rigmora Biotech Investor One LP, by its general partner Unicorn Biotech Ventures One Ltd, and Rigmora Biotech Investor Two LP, by its general partner Unicorn Biotech Ventures Two Ltd (collectively, the "**LPs**"), by and through their undersigned counsel, hereby file this exhibit list (the "**Exhibit List**") identifying the exhibits the LPs may introduce into evidence in connection with the *Debtors' Motion for Entry of Interim and Final Orders to (I) Continue Employee Benefits Programs and (II) Granting Related Relief* [Docket No. 23]; *Debtors' Motion Seeking Entry of Interim and Final Orders (I) Authorizing the Debtor to (A) Continue to Operate Their Cash Management System, (B) Honor Certain Pre-Petition Obligations Related Thereto, and (C) Continue to Perform Intercompany Transactions, (II) Granting Administrative Expense Status to Post-Petition Intercompany Balances, and (III) Granting Related Relief* [Docket No. 24]; *Debtors' Motion for an Order (I) Enforcing the Automatic Stay and (II) Imposing Sanctions Against Rigmora* [Docket No. 83]; *Debtors' Motion for Entry of Interim and Final Orders to (I)*

[1] The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); Nine Square Therapeutics, Inc. (4503); and Nereid Therapeutics Incorporated (8493). The location of the Debtors' service address in these chapter 11 cases is 230 Park Avenue, Suite 2800, New York, NY 10169.

Make and Accept Secured Loans to Portfolio Companies, (II) Authorize to the Extent Outside the Ordinary Course of Business Payment of Management Company Expenses and (III) Grant Related Relief [Docket No. 89]; *Debtors' Motion for Entry of an Order (I) Authorizing Debtors to Employ Professionals Utilized in the Ordinary Course of Business, (II) Waiving Certain Information Requirements of Local Rule 2016-1, and (III) Granting Related Relief* [Docket No. 121] at the hearing scheduled on January 20, 2026 at 2:30 p.m. (ET) (the "**Hearing**") before the Honorable Laurie S. Silverstein, at the United States Bankruptcy Court for the District of Delaware, 824 N. Market Street, 6th Floor, Courtroom No. 2, Wilmington, Delaware 19801.

The LPs reserve the right to ask the Court to take judicial notice of pleadings, transcripts, and/or documents filed in or in connection with the above-captioned cases, to offer rebuttal exhibits, and to modify, supplement, or amend this Exhibit List at any time prior to or during the Hearing. Designation of any exhibit below does not waive any objections the LPs may have to any exhibit listed on any party's exhibit list or introduced at the hearing.

EXHIBIT	DESCRIPTION
1	Voluntary Petition for ATP Life Sciences Venture, L.P., Dkt. 1 (Case No. 25-12178)
2	Voluntary Petition for Nereid Therapeutics Incorporated, Dkt. 1 (Case No. 26-10048)
3	Declaration of Dr. Seth L. Harrison in Support of Chapter 11 Petitions ad First Day Motions, Dkt. 18
4	Supplemental Declaration of Perry M. Mandarino, Chief Restructuring Officer of the Debtors, in Support of Chapter 11 Petitions and First Day Motions, Dkt. 63
5	Debtors' Motion for Entry of Interim and Final Orders to (I) Make and Accept Secured Loans to Portfolio Companies, (II) Authorize to the Extent Outside the Ordinary Course of Business Payment of Management Company Expenses and (III) Grant Related Relief, Dkt. 89
6	Declaration of Perry Mandarino in Support of Debtors' Motion for Entry of Interim and Final Orders to (I) Make and Accept Secured Loans to Portfolio Companies, (II) Authorize to the Extent Outside the Ordinary Course of Business Payment of Management Company Expenses, Dkt. 90
7	Rigmora's Opposition to Debtors' Motion to Enforce the Automatic Stay and Impose Sanctions (Dkt. 117)
8	**(Sealed)** Rigmora's Limited Omnibus Objection to Debtors' Operational Motions, Dkt. 143

9	Debtors' Reply to Limited Omnibus Objection to Rigmora Biotech Investor One LP and Rigmora Biotech Investor Two LP to Debtors' Motion for Entry of Interim and Final Orders to (I) Make and Accept Secured Loans to Portfolio Companies, (II) Authorize to the Extent Outside the Ordinary Course of Business Payment of Management Company Expenses and (III) Granting Related Relief and Debtors' Other Operational Motions and Supplements Thereto, Dkt. 160
10	Email from W.H. Taft, January 13, 2026
11	Stoke and Akero Option Consent, Nov. 11, 2019 (Dkt. 143, Ex. W)
12	Stoke and Akero Option Consent, Dec. 28, 2020 (Dkt. 143, Ex. X)
13	Akero and Novo Nordisk Press Release
14	**(Sealed)** Jan. 6, 2021 email exchange between D. Finkelman and P. Blochlinger re: Management Fee Reduction (RIGMORA00034760)
15	Chancery JX-0001, First Amended and Restated Limited Partnership Agreement ("LPA") (Dkt. 143, Ex. F)
16	Chancery JX-0009, LPA Amendment No. 7
17	Chancery JX-0010, LPA Amendment No. 8
18	Chancery JX-0015, LPA Amendment No. 13 (Dkt. 143, Ex. K)
19	LPA Amendment No. 14 (Dkt. 160, Ex. E)
20	Amendment to Management Agreement, dated August 2017
21	Chancery JX-2275, Q2 2025 Quarterly Digest (Dkt. 143, Ex. C)
22	Chancery JX-2280, ATP October 2025 Pitchdeck
23	Budget, filed by Debtors Dec. 17, 2025 (Dkt. 63-1)
24	Budget ATPBK00000001 (native), produced December 28, 2025
25	Budget Newton Portco - ATP Interim Funding Motion Support (native), emailed December 29, 2025
26	Budget Newton Portco - ATP Interim Funding Motion Support_v2 (native), emailed December 30, 2025
27	Budget Project Newton - 13 Week Cashflow - 2026.01.11vFF (native), emailed January 11, 2026
28	Budget Project Newton - 13 Week Cashflow - 2026.01.11vFF - 97M vDIST, filed January 16, 2026 (Dkt. 160-1)
29	Budget Project Newton - 13 Week Cashflow - 2026.01.11vFF - 97M vDIST (native), emailed January 16, 2026
30	26-Week Budget, filed January 16, 2026 (Dkt. 163-2)
31	Rigmora Diligence Questions to Debtors, January 12, 2026

32	Chancery Post-Trial Opinion, *ATP III, GP, LTD., v. Rigmora Biotech Investor One LP and Rigmora Biotech Investor Two LP*, Chancery Court of Delaware, December 5, 2025 (Dkt. 143, Ex. A)
33	**(Sealed)** Chancery Yanchik II Dep. Transcript (Dkt. 143, Ex. B)
34	Chancery JX-1212, Q4 2024 Quarterly Digest (Dkt. 143, Ex. D)
35	Chancery Trial Transcript, Oct. 16-17, 2025 (Dkt. 143, Ex. E)
36	Chancery ATP Pre-Trial Brief (Dkt. 143, Ex. G)
37	Chancery ATP Post-Trial Reply Br. (Dkt. 143, Ex. H)
38	Chancery Dr. Strebulaev Expert Report (Dkt. 143, Ex. I)
39	Sept. 8, 2025 Letter from Walkers (Dkt. 143, Ex. J)
40	Chancery ATP Post-Trial Br. (Dkt. 143, Ex. L)
41	Apertor Secured Promissory Note (Dkt. 143, Ex. M)
42	Evercrisp Secured Promissory Note (Dkt. 143, Ex. N)
43	Initial Secured Promissory Note (Dkt. 143, Ex. O)
44	Marlinspike Secured Promissory Note (Dkt. 143, Ex. P)
45	Nereid Secured Promissory Note (Dkt. 143, Ex. Q)
46	Nine Square Secured Promissory Note (Dkt. 143, Ex. R)
47	Chancery JX-0004, LPA Amendment No. 3 (Dkt. 143, Ex. S)
48	Email from W.H. Taft, January 11, 2026 (Dkt. 143, Ex. T)
49	Chancery Dr. Rao Expert Report (Dkt. 143, Ex. U)
50	Dr. Rimm Expert Report (Dkt. 143, Ex. V)
51	Plaintiffs'/Petitioners' Skeleton Argument for PTR (Dkt. 117, Ex. A)
52	Correspondence from Cayman Court, Dec. 11, 2025 (Dkt. 117, Ex. B)
53	Correspondence from Quinn Emanuel to H. Farmer, Dec. 11, 2025 (Dkt. 117, Ex. C)
54	Correspondence from Walkers to Cayman Court, Dec. 8, 2025 (Dkt. 117, Ex. D)
55	Transcript of Cayman Pre-Trial Review, Dec. 17, 2025 (Dkt. 117, Ex. E)

56	Judgment of Cayman Court, Dec. 22, 2025, *Unicorn Biotech Ventures One Ltd v ATP II GP Ltd* [2025] CIGC (FSD) 124 (Dkt. 117, Ex. F)
57	*In the Matters of Soundview Elite Ltd, Soundview Premium Ltd, Soundview Star Ltd* [2013] CIGC J1213-1 (Dkt. 117, Ex. G)
58	Perry Mandarino Dep. Transcript, Jan. 19, 2026

Dated: January 19, 2026
Wilmington, Delaware

Respectfully Submitted,

RICHARDS, LAYTON & FINGER, P.A.

/s/ Nicholas A. Franchi
John H. Knight (No. 3848)
Michael J. Merchant (No. 3854)
Daniel E. Kaprow (No. 6295)
Clint M. Carlisle (No. 7313)
Nicholas A. Franchi (No. 7401)
One Rodney Square
920 North King Street
Wilmington, DE 19801
Telephone: (302) 651-7700
Facsimile: (302) 651-7701
Email: knight@rlf.com
merchant@rlf.com
kaprow@rlf.com
carlisle@rlf.com
franchi@rlf.com

DEBEVOISE & PLIMPTON LLP

Shannon Rose Selden (admitted *pro hac vice*)
M. Natasha Labovitz (admitted *pro hac vice*)
William H. Taft V (admitted *pro hac vice*)
Zachary H. Saltzman (admitted *pro hac vice*)
Natascha Born (admitted *pro hac vice*)
Carl Micarelli (admitted *pro hac vice*)
Sebastian Dutz (admitted *pro hac vice*)
66 Hudson Boulevard
New York, New York 10001
Telephone: (212) 909-6000
Email: srselden@debevoise.com
nlabovitz@debevoise.com
whtaft@debevoise.com
zsaltzman@debevoise.com
nborn@debevoise.com
cmicarelli@debevoise.com
spdutz@debevoise.com

Counsel for Rigmora Biotech Investor One LP (by and through its general partner Unicorn Biotech Ventures One Ltd) and Rigmora Biotech Investor Two LP (by and through its general partner Unicorn Biotech Ventures Two Ltd)